zurück zur Übersicht

Christina Kratzer,(1) Elisabeth Presterl,(1) Selma Tobudic,(1) Wolfgang Graninger,(1)
Birgit Willinger (2)

(1) Med. Universität Wien - Innere Medizin I
Abt. für Infektionen & Tropenmedizin
Währinger Gürtel 18-20
A – 1090 Wien
Tel: +43/1/40400-4440
E-Mail: christina.kratzer@meduniwien.ac.at

(2) Med. Universität Wien
Klin. Institut für Hygiene und Med. Mikrobiologie
Abt. für Klin. Mikrobiologie

During a 6-months period Candida isolates of patients with invasive infections were tested for their susceptibility against posaconazole, voriconazole, caspofungin, fluconazole and itraconazole. Clinical Candida isolates from unique patients were collected from blood culture or central venous catheter from July to December 2006. Susceptibility testing was performed by using the E-test. Species distribution of 57 invasive Candida spp. isolates was as follows: 56.1% Candida albicans, 21.1% Candida parapsilosis, 14% Candida glabrata, 3.5% Candida tropicalis, 1.8% Candida krusei, 1.8% Candida lusitaniae and 1.8% other Candida spp. The MIC50 and MIC90 were 0.047 mg/l and 1 mg/l for posaconazole, 0.06 mg/l and 0.3 mg/l for voriconazole, 0.125 mg/l and 0.5 mg/l for caspofungin, 1 mg/l and 64 mg/l for fluconazole, 0.125 mg/l and 1.2 mg/l for itraconazole, respectively. Out of the 6 (10.7%) fluconazole-resistant isolates, all strains exhibited resistance to itraconazole, 3 strains (5.3%) exhibited resistance to voriconazole and 4 isolates (7%) had MICs of posaconazole > 1 mg/l. No cross-resistance was detected for caspofungin. Overall, resistance rates among invasive Candida isolates are low, however, continuous susceptibility testing for invasive isolates in particular, seems to be warranted.